Free Newsletter
Blocking enzyme effective in preventing breast cancer
Scientists at Canada's McGill University say blocking the enzyme PTP1B delayed cancer in mice that also respond to Herceptin. They add development of new drugs that can block the enzyme could well boost the effectiveness of other therapies in humans. The team concentrated on a strain of mice that develops breast cancer as the result of over-activity in the Her-2 gene, a trigger in about one quarter of all breast cancer cases and a biomarker for Heceptin. In addition to delaying the onset of breast tumors, researchers said deleting PTP1B also prevented secondary lung tumors.They noted that in animal studies, the benefits of treatment lasted two months after two weeks of therapy.
- here's the report on the research from the BBC
More stories about biomarkers
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment